Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate. The EDSA stock yearly return is shown above.
The yearly return on the EDSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EDSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|